UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
UNAIDS and DPKO non paper | 2011
Strengthening Community responses to HIv Treatment and Prevention
Vision 2030
Accessed: 17.11.2019
UNAIDS 2018 / Guidance
Guidance for policy-makers, and people living with, at risk of or affected by HIV
UNAIDS | 2016–2021 Strategy
Accessed: 20.11.2019
Overwhelming evidence shows that a range of health concerns—mental illness, substance dependence, HIV/AIDS, and noncommunicable diseases—affect prisoners disproportionately. But, while incarceration poses risks to health—including inadequate nutrition and exposure to violence—prisons also pr...esent important opportunities to promote health and risk reduction that need to be tapped.
Some recommended remedies:
Health ministries, not ministries of justice, should manage health care responsibilities
Ensure that testing is available, but not mandatory, for infectious diseases
Make prison health part of the broader public health agenda
more
Regional Initiative for the Elimination of Mother-to-Child Transmission of HIV and Congenital Syphilis in Latin America and the Caribbean
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
PLoSONE 12(9):e0184986.https://doi.org/10.1371/journal.pone.0184986
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis